Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Journal of Biopharmaceutical Statistics
|
February 13, 2019
R-TPI: rolling toxicity probability interval design to shorten the duration and maintain safety of phase I trials
Wentian Guo, Yuan Ji, Daniel Li
Statistics in Biosciences
|
November 4, 2015
TEAMS: Toxicity- and Efficacy-based Dose Insertion Design with Adaptive Model Selection for Phase I/II Dose-Escalation Trials in Oncology
Wentian Guo, Yang Ni, Yuan Ji
JCO Precision Oncology
|
September 14, 2020
Bayesian Approaches to Subgroup Analysis and Related Adaptive Clinical Trial Designs
Ciara Nugent, Wentian Guo, Peter Müller, et al.
Biometrics
|
October 25, 2016
A subgroup cluster-based Bayesian adaptive design for precision medicine
Wentian Guo, Yuan Ji, Daniel V T Catenacci
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 16, 2016
Toxicity and Efficacy Probability Interval Design for Phase I Adoptive Cell Therapy Dose-Finding Clinical Trials
Daniel H Li, James B Whitmore, Wentian Guo, et al.
Contemporary Clinical Trials
|
May 2, 2017
A Bayesian interval dose-finding design addressingOckham's razor: mTPI-2
Wentian Guo, Sue-Jane Wang, Shengjie Yang, et al.
Scientific Reports
|
December 8, 2015
Deciphering Genomic Underpinnings of Quantitative MRI-based Radiomic Phenotypes of Invasive Breast Carcinoma
Yitan Zhu, Hui Li, Wentian Guo, et al.
Journal of Parkinson'S Disease
|
May 3, 2021
Plasma Short-Chain Fatty Acids Differences in Multiple System Atrophy from Parkinson's Disease
Xiaoqin He, Yiwei Qian, Shaoqing Xu, et al.
Journal of Medical Imaging (Bellingham, Wash.)
|
February 3, 2016
Prediction of clinical phenotypes in invasive breast carcinomas from the integration of radiomics and genomics data
Wentian Guo, Hui Li, Yitan Zhu, et al.
Nature Communications
|
April 5, 2022
Neutralizing activity of BBIBP-CorV vaccine-elicited sera against Beta, Delta and other SARS-CoV-2 variants of concern
Xiaoqi Yu, Dong Wei, Wenxin Xu, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Journal of Biopharmaceutical Statistics
|
February 13, 2019
R-TPI: rolling toxicity probability interval design to shorten the duration and maintain safety of phase I trials
Wentian Guo, Yuan Ji, Daniel Li
Statistics in Biosciences
|
November 4, 2015
TEAMS: Toxicity- and Efficacy-based Dose Insertion Design with Adaptive Model Selection for Phase I/II Dose-Escalation Trials in Oncology
Wentian Guo, Yang Ni, Yuan Ji
JCO Precision Oncology
|
September 14, 2020
Bayesian Approaches to Subgroup Analysis and Related Adaptive Clinical Trial Designs
Ciara Nugent, Wentian Guo, Peter Müller, et al.
Biometrics
|
October 25, 2016
A subgroup cluster-based Bayesian adaptive design for precision medicine
Wentian Guo, Yuan Ji, Daniel V T Catenacci
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 16, 2016
Toxicity and Efficacy Probability Interval Design for Phase I Adoptive Cell Therapy Dose-Finding Clinical Trials
Daniel H Li, James B Whitmore, Wentian Guo, et al.
Contemporary Clinical Trials
|
May 2, 2017
A Bayesian interval dose-finding design addressingOckham's razor: mTPI-2
Wentian Guo, Sue-Jane Wang, Shengjie Yang, et al.
Scientific Reports
|
December 8, 2015
Deciphering Genomic Underpinnings of Quantitative MRI-based Radiomic Phenotypes of Invasive Breast Carcinoma
Yitan Zhu, Hui Li, Wentian Guo, et al.
Journal of Parkinson'S Disease
|
May 3, 2021
Plasma Short-Chain Fatty Acids Differences in Multiple System Atrophy from Parkinson's Disease
Xiaoqin He, Yiwei Qian, Shaoqing Xu, et al.
Journal of Medical Imaging (Bellingham, Wash.)
|
February 3, 2016
Prediction of clinical phenotypes in invasive breast carcinomas from the integration of radiomics and genomics data
Wentian Guo, Hui Li, Yitan Zhu, et al.
Nature Communications
|
April 5, 2022
Neutralizing activity of BBIBP-CorV vaccine-elicited sera against Beta, Delta and other SARS-CoV-2 variants of concern
Xiaoqi Yu, Dong Wei, Wenxin Xu, et al.
Page
of 2